Merck & Co and Sun Pharmaceutical are winding down their 2011 joint venture focused on developing branded generics for emerging markets outside of India.
Sun Pharma said the move follows a change of strategic priorities for both partners, which have decided not to invest further in the JV.
Dilip Shanghvi, Sun’s managing director, reportedly told analysts that the firm’s investment in the venture is not significant and has been factored into the company’s financials over time, according to The Hindu Business Line.
Other agreements between the firms – the co-marketing deal for Merck’s diabetes drug Januvia (sitagliptin) and licensing deal for Merck’s investigational psoriasis therapy tildrakizumab – remain unaffected by the decision, the Indian generics giant stressed.
By Selina McKee
Source: Pharma Times
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.